A cell biological view of Toll-like receptor function: regulation through compartmentalization

Division of Immunology and Pathogenesis, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California 94720-3200, USA.
Nature Reviews Immunology 07/2009; 9(8):535-42. DOI: 10.1038/nri2587
Source: PubMed

ABSTRACT An emerging paradigm in innate immune signalling is that cell biological context can influence the outcome of a ligand-receptor interaction. In this Review we discuss how Toll-like receptor (TLR) activation and signal transduction are regulated by subcellular compartmentalization of receptors and downstream signalling components. In particular, we focus on the functional specialization of TLRs in the endosomal system. We discuss recent studies that illustrate how basic aspects of the cellular machinery contribute to TLR function and regulation. This emerging area of research will provide important information on how immune signal transduction networks depend on (and in some cases influence) the generic regulators that organize eukaryotic cells.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Toll-like receptors (TLRs) of the innate immune system are unusual in that individual family members are located on different organelles, yet most activate a common signaling pathway important for host defense. It remains unclear how this common signaling pathway can be activated from multiple subcellular locations. Here, we report that, in response to natural activators of innate immunity, the sorting adaptor TIRAP regulates TLR signaling from the plasma membrane and endosomes. TLR signaling from both locations triggers the TIRAP-dependent assembly of the myddosome, a protein complex that controls proinflammatory cytokine expression. The actions of TIRAP depend on the promiscuity of its phosphoinositide-binding domain. Different lipid targets of this domain direct TIRAP to different organelles, allowing it to survey multiple compartments for the presence of activated TLRs. These data establish how promiscuity, rather than specificity, can be a beneficial means of diversifying the subcellular sites of innate immune signal transduction.
    Cell 02/2014; 156(4):705-16. DOI:10.1016/j.cell.2014.01.019
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 2 toll-like receptors (TLR2) are expressed in cell membranes and recognize a wide range of pathogen-associated molecular patterns derived from bacteria, such as lipoteichoic acid (LTA). Aims: To evaluate the effect of TLR2 activation by LTA on the activity of type 1 Na+/H+ exchanger (NHE) in T84 intestinal epithelial cells. Results: Short-term (0.5 h) and long-term (18 h) TLR2 activation significantly inhibited NHE activity in a concentration dependent manner (0.01-100 µg/ml; -7±3 to -21±3% and 3±3 to -21±3% of control values, respectively). S3226, a NHE3 selective inhibitor, did not affect the inhibitory effect upon NHE activity. NHE inhibition LTA-induced was absent in the presence of EIPA (NHE1 inhibitor). Long-term TLR2 activation decreased NHE1 affinity for Na+ (Km= 65.0±1.7 mM) compared to control (Km= 20.4±0.5 mM) without changes in Vmax values. Following TLR2 activation tyrosine-protein kinase (SRC) activation, phosphatidylinositol 3-kinase (PI3K) recruitment and adenylyl cyclase 3 (AC3) phosphorylation was observed. The total amount of AC3 increased (23±8 % of control) after long-term treatment with LTA. Anti-AC3 siRNA prevented LTA-induced NHE1 inhibition, similarly to that observed with the AC3 inhibitor KH7. A significant increase in cAMP levels (32±3% and 14±2% after short- and long-term stimulation, respectively) was detected and inhibition of protein kinase A (PKA), phospholipase C (PLC), and downregulation of protein kinase C (PKC) prevented NHE1 inhibition. Inhibition of NF-kβ failed to revert NHE1 inhibition. Conclusions: Activation of TLR2 reduces NHE1 activity in epithelial cells through an alternative pathway, unrelated to NF-kβ, which involves SCR, PI3K, AC3, PKA, PLC and PKC.
    Journal of Pharmacology and Experimental Therapeutics 07/2013; 346(3). DOI:10.1124/jpet.113.204602
  • Source


Available from